128 related articles for article (PubMed ID: 26909615)
1. Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications.
Lange SE; Zheleznyak A; Studer M; O'Shannessy DJ; Lapi SE; Van Tine BA
Oncotarget; 2016 Mar; 7(11):13082-92. PubMed ID: 26909615
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas.
Jones RL; Chawla SP; Attia S; Schöffski P; Gelderblom H; Chmielowski B; Le Cesne A; Van Tine BA; Trent JC; Patel S; Wagner AJ; Chugh R; Heyburn JW; Weil SC; Wang W; Viele K; Maki RG
Cancer; 2019 Jul; 125(14):2445-2454. PubMed ID: 31034598
[TBL] [Abstract][Full Text] [Related]
3. Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.
Pool M; Kol A; Lub-de Hooge MN; Gerdes CA; de Jong S; de Vries EG; Terwisscha van Scheltinga AG
Oncotarget; 2016 Oct; 7(42):68111-68121. PubMed ID: 27602494
[TBL] [Abstract][Full Text] [Related]
4. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats.
Brouwers A; Verel I; Van Eerd J; Visser G; Steffens M; Oosterwijk E; Corstens F; Oyen W; Van Dongen G; Boerman O
Cancer Biother Radiopharm; 2004 Apr; 19(2):155-63. PubMed ID: 15186595
[TBL] [Abstract][Full Text] [Related]
5. Novel antibody probes for the characterization of endosialin/TEM-1.
O'Shannessy DJ; Smith MF; Somers EB; Jackson SM; Albone E; Tomkowicz B; Cheng X; Park Y; Fernando D; Milinichik A; Kline B; Fulton R; Oberoi P; Nicolaides NC
Oncotarget; 2016 Oct; 7(43):69420-69435. PubMed ID: 27494870
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.
D'Angelo SP; Hamid OA; Tarhini A; Schadendorf D; Chmielowski B; Collichio FA; Pavlick AC; Lewis KD; Weil SC; Heyburn J; Schweizer C; O'Shannessy DJ; Carvajal RD
Invest New Drugs; 2018 Feb; 36(1):103-113. PubMed ID: 29127533
[TBL] [Abstract][Full Text] [Related]
7. Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin.
Chacko AM; Li C; Nayak M; Mikitsh JL; Hu J; Hou C; Grasso L; Nicolaides NC; Muzykantov VR; Divgi CR; Coukos G
J Nucl Med; 2014 Mar; 55(3):500-507. PubMed ID: 24525208
[TBL] [Abstract][Full Text] [Related]
8. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.
Nagengast WB; de Vries EG; Hospers GA; Mulder NH; de Jong JR; Hollema H; Brouwers AH; van Dongen GA; Perk LR; Lub-de Hooge MN
J Nucl Med; 2007 Aug; 48(8):1313-9. PubMed ID: 17631557
[TBL] [Abstract][Full Text] [Related]
9. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.
Aerts HJ; Dubois L; Perk L; Vermaelen P; van Dongen GA; Wouters BG; Lambin P
J Nucl Med; 2009 Jan; 50(1):123-31. PubMed ID: 19091906
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of ⁸⁹Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model.
Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
Nucl Med Commun; 2015 Mar; 36(3):286-94. PubMed ID: 25460304
[TBL] [Abstract][Full Text] [Related]
11. Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.
Fleuren ED; Versleijen-Jonkers YM; van de Luijtgaarden AC; Molkenboer-Kuenen JD; Heskamp S; Roeffen MH; van Laarhoven HW; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
Clin Cancer Res; 2011 Dec; 17(24):7693-703. PubMed ID: 22038993
[TBL] [Abstract][Full Text] [Related]
12. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
ter Weele EJ; Terwisscha van Scheltinga AG; Kosterink JG; Pot L; Vedelaar SR; Lamberts LE; Williams SP; Lub-de Hooge MN; de Vries EG
Oncotarget; 2015 Dec; 6(39):42081-90. PubMed ID: 26536664
[TBL] [Abstract][Full Text] [Related]
13. Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a.
Burvenich IJ; Parakh S; Gan HK; Lee FT; Guo N; Rigopoulos A; Lee ST; Gong S; O'Keefe GJ; Tochon-Danguy H; Kotsuma M; Hasegawa J; Senaldi G; Scott AM
J Nucl Med; 2016 Jun; 57(6):974-80. PubMed ID: 26940768
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).
Norris RE; Fox E; Reid JM; Ralya A; Liu XW; Minard C; Weigel BJ
Pediatr Blood Cancer; 2018 May; 65(5):e26944. PubMed ID: 29292843
[TBL] [Abstract][Full Text] [Related]
15. Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies.
Rouleau C; Gianolio DA; Smale R; Roth SD; Krumbholz R; Harper J; Munroe KJ; Green TL; Horten BC; Schmid SM; Teicher BA
Mol Cancer Ther; 2015 Sep; 14(9):2081-9. PubMed ID: 26184481
[TBL] [Abstract][Full Text] [Related]
16. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.
Oude Munnink TH; Korte MA; Nagengast WB; Timmer-Bosscha H; Schröder CP; Jong JR; Dongen GA; Jensen MR; Quadt C; Hooge MN; Vries EG
Eur J Cancer; 2010 Feb; 46(3):678-84. PubMed ID: 20036116
[TBL] [Abstract][Full Text] [Related]
17. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
18. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma.
Rouleau C; Curiel M; Weber W; Smale R; Kurtzberg L; Mascarello J; Berger C; Wallar G; Bagley R; Honma N; Hasegawa K; Ishida I; Kataoka S; Thurberg BL; Mehraein K; Horten B; Miller G; Teicher BA
Clin Cancer Res; 2008 Nov; 14(22):7223-36. PubMed ID: 19010839
[TBL] [Abstract][Full Text] [Related]
19. Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice.
Alsaid H; Skedzielewski T; Rambo MV; Hunsinger K; Hoang B; Fieles W; Long ER; Tunstead J; Vugts DJ; Cleveland M; Clarke N; Matheny C; Jucker BM
PLoS One; 2017; 12(4):e0176075. PubMed ID: 28448604
[TBL] [Abstract][Full Text] [Related]
20. Immuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical Role.
Yuan Q; Furukawa T; Tashiro T; Okita K; Jin ZH; Aung W; Sugyo A; Nagatsu K; Endo H; Tsuji AB; Zhang MR; Masuko T; Inoue M; Fujibayashi Y; Saga T
PLoS One; 2015; 10(11):e0143076. PubMed ID: 26571416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
